Business Context and Reporting Period
Nasus Pharma Ltd., a foreign private issuer, filed Form 6-K on September 18, 2026. The filing reports the execution of an At-The-Market (ATM) Sales Agreement with BTIG, LLC to facilitate the potential sale of ordinary shares.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the authorization of a new equity financing mechanism. Nasus Pharma entered into a Sales Agreement allowing it to sell ordinary shares from time to time through BTIG, LLC as the sales agent. The company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Management Commentary
- Use of Proceeds: Management intends to use net proceeds for the ongoing clinical development of NS002 for anaphylaxis treatment, the initiation of clinical studies for other pipeline products, and working capital/general corporate purposes.
- Transaction Terms: The Sales Agent will receive a commission of up to 3.0% of aggregate gross proceeds. Sales will be conducted as "at the market offerings" under Rule 415(a)(4).
- Risks and Contingencies: The company's ability to raise capital is subject to market conditions and the Sales Agent's commercially reasonable efforts. The filing includes standard legal disclaimers regarding the legality of the offer in various jurisdictions.
Investor Verification Checklist
- Verify the current cash position and burn rate to assess the immediate necessity of the ATM facility.
- Review the status of the NS002 clinical trials for anaphylaxis to evaluate the primary use of proceeds.
- Monitor future filings for actual share issuances and the impact on shareholder dilution.
- Confirm the terms of the 3.0% commission and any additional reimbursement obligations to BTIG, LLC.